Manas Mishra has covered the healthcare and pharmaceuticals sector since 2017. He joined Norstella from Reuters, where he spent 8 years covering a range of breaking news stories ranging from vaccine development during the peak of the COVID-19 pandemic, to the killing of UnitedHealthcare CEO Brian Thompson. Manas was the Editor-in-Charge of the Bangalore health and pharmaceuticals team at Reuters between 2022-2025. When not looking for stories, Manas enjoys attending rock and metal concerts, swimming and reading science fiction.
Latest from Manas Mishra
Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.
The CEOs of two early-stage biotechs explain to Scrip why investor interest in ocular gene therapies is surging and how they aim to attract big pharma partners.
Satellos is moving to start a double-blinded Phase II trial of its experimental Duchenne muscular dystrophy candidate that looks to mimic the effects of dystrophin on muscle stem cells.
The second cycle of IRA price negotiations could result in price cuts as high as 85% to the 2024 list prices, but the mean discount across the 15 negotiated drugs appears similar to the previous round.
The second cycle of IRA price negotiations could result in price cuts as high as 85% to the 2024 list prices, but the mean discount across the 15 negotiated drugs appears similar to the previous round.
Clinical Data Readout: Armed with positive data from the first Phase III trial of a China-made subcutaneous anti-PD-1 antibody, Junshi is chasing other heavyweights such as Keytruda and Opdivo, as well as a domestic rival.